Last reviewed · How we verify

Control (insulin Novorapid)

Rigshospitalet, Denmark · Phase 3 active Small molecule

Control (insulin Novorapid) is a Rapid-acting insulin analog Small molecule drug developed by Rigshospitalet, Denmark. It is currently in Phase 3 development for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: First generation insulin analog.

Insulin aspart (NovoRapid) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization.

Insulin aspart (NovoRapid) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameControl (insulin Novorapid)
Also known asFirst generation insulin analog
SponsorRigshospitalet, Denmark
Drug classRapid-acting insulin analog
TargetInsulin receptor (IR)
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Insulin aspart is a genetically engineered insulin analog with a single amino acid substitution that allows faster absorption and onset of action compared to human insulin. It mimics the body's natural insulin response by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This rapid action makes it suitable for mealtime glucose control in diabetes management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Control (insulin Novorapid)

What is Control (insulin Novorapid)?

Control (insulin Novorapid) is a Rapid-acting insulin analog drug developed by Rigshospitalet, Denmark, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does Control (insulin Novorapid) work?

Insulin aspart (NovoRapid) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization.

What is Control (insulin Novorapid) used for?

Control (insulin Novorapid) is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes Control (insulin Novorapid)?

Control (insulin Novorapid) is developed by Rigshospitalet, Denmark (see full Rigshospitalet, Denmark pipeline at /company/rigshospitalet-denmark).

Is Control (insulin Novorapid) also known as anything else?

Control (insulin Novorapid) is also known as First generation insulin analog.

What drug class is Control (insulin Novorapid) in?

Control (insulin Novorapid) belongs to the Rapid-acting insulin analog class. See all Rapid-acting insulin analog drugs at /class/rapid-acting-insulin-analog.

What development phase is Control (insulin Novorapid) in?

Control (insulin Novorapid) is in Phase 3.

What are the side effects of Control (insulin Novorapid)?

Common side effects of Control (insulin Novorapid) include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does Control (insulin Novorapid) target?

Control (insulin Novorapid) targets Insulin receptor (IR) and is a Rapid-acting insulin analog.

Related